




Formula (I)

wherein:

- one of X and Y is an N atom or C substituted with a fluorine atom, and the other is CH;
- R^1 is C_{5-6} alkyl, which is unsubstituted or substituted with one, two, three or four fluorine atoms, R^1 is cyclohexyl which is unsubstituted or substituted with one or two -OH groups, or R^1 is unsubstituted tetrahydropyran;
- m is 1
- L is a single bond or C_1 alkylene; and
- Z is NH_2 ;


or a pharmaceutically acceptable salt thereof.

In another aspect of the present disclosure, there is provided a pharmaceutical composition which comprises a compound as defined herein and a pharmaceutically acceptable carrier or diluent.

In yet another aspect of the present disclosure, there is provided a compound as defined herein, for use in the treatment of the human or animal body by therapy.

CLAIMS

- 5 1. A compound which is a benzimidazole of formula (I):



Formula (I)

wherein:

- 10 - one of X and Y is an N atom or C substituted with a fluorine atom, and the other is CH;
- 15 - R¹ is C₅₋₆ alkyl, which is unsubstituted or substituted with one, two, three or four fluorine atoms, R¹ is cyclohexyl which is unsubstituted or substituted with one or two -OH groups, or R¹ is unsubstituted tetrahydropyran;
- 20 - m is 1
- L is a single bond or C₁ alkylene; and
- Z is NH₂;

or a pharmaceutically acceptable salt thereof.

25

30

2. A compound according to claim 1 which is selected from:

5

- 1'-{[5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-1,3-benzodiazol-2-yl]methyl}-6'-fluoro-1',2'-dihydrospiro[cyclopropane-1,3'-indole]-2'-one;
- 1'-((5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzo[d]imidazol-2-yl)methyl)spiro[cyclopropane-1,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one;
- 10 - 1'-((5-(aminomethyl)-1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)spiro[cyclopropane-1,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one;
- 1'-((5-(aminomethyl)-1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)spiro[cyclopropane-1,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one; and
- 1'-((5-(aminomethyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-yl)methyl)-6'-fluorospiro[cyclopropane-1,3'-indolin]-2'-one;
- 15 - 1'-((5-(Aminomethyl)-1-((1R,4R)-4-hydroxycyclohexyl)-1H-benzo[d]imidazol-2-yl)methyl)-6'-fluorospiro[cyclopropane-1,3'-indolin]-2'-one

and the pharmaceutically acceptable salts thereof.

20

3. A pharmaceutical composition which comprises a compound as defined in claim 1 or 2 and a pharmaceutically acceptable carrier or diluent.

25

30

35

4. A compound as defined in claim 1 or 2, for use in the treatment of the human or animal body by therapy.

5

5. A compound as defined in claim 1 or 2 for use in the treatment or prevention of an RSV infection.

6. A product containing:

10

(a) a compound as defined in claim 1 or 2; and

(b) one or more further therapeutic agents;

for simultaneous, separate or sequential use in the treatment of a subject suffering from or susceptible to an RSV infection.

15

7. A product for use according to claim 6, wherein the further therapeutic agent is :

(i) a RSV nucleocapsid(N)-protein inhibitor;

(ii) another protein inhibitor, such as one that inhibits the phosphoprotein (P) protein and/or large (L) protein;

20

(iii) an anti-RSV monoclonal antibody, such as an F-protein antibody;

(iv) an immunomodulating toll-like receptor compound;

(v) another respiratory virus anti-viral, such as an anti-influenza and/or anti-rhinovirus compound; and/or

(vi) an anti-inflammatory compound.

25

8. A pharmaceutical composition which comprises (a) a compound as defined in claim 1 or 2, and (b) one or more further therapeutic agents, as defined in claim 6 or 7, together with a pharmaceutically acceptable carrier or diluent.